| Page 1964 | Kisaco Research
Quick-Look Agenda
 

Heather Wasserman

Senior Director
Eli Lilly and Company

Heather Wasserman

Senior Director
Eli Lilly and Company

Heather Wasserman

Senior Director
Eli Lilly and Company
 

Ailis Tweed-Kent

CEO
Cocoon Biotech

Dr. Ailis Tweed-Kent is an up-and-coming entrepreneur and leader in the development of innovative medical technologies. With her education in medicine at Harvard Medical School (HMS) and residency in internal medicine at Massachusetts General Hospital (MGH), Ailis has first-hand knowledge of the burden of disease. In 2013, Ailis was inspired by her patients to found Cocoon to develop innovative silk therapeutics for osteoarthritis.

Ailis Tweed-Kent

CEO
Cocoon Biotech

Ailis Tweed-Kent

CEO
Cocoon Biotech

Dr. Ailis Tweed-Kent is an up-and-coming entrepreneur and leader in the development of innovative medical technologies. With her education in medicine at Harvard Medical School (HMS) and residency in internal medicine at Massachusetts General Hospital (MGH), Ailis has first-hand knowledge of the burden of disease. In 2013, Ailis was inspired by her patients to found Cocoon to develop innovative silk therapeutics for osteoarthritis. Prior to Cocoon, she worked on the design, development, and delivery of diagnostic technologies for global health collaborating with organizations such as PEPFAR/Office of U.S. Global AIDS Coordinator, London School of Hygiene & Tropical Medicine, and the Global Health Delivery Project. She brings a multidisciplinary approach with a B.S. in Chemical Engineering from the University of Notre Dame.

 

Dorothy Brown

Senior Research Advisor, Translational Comparative Medical Research (TCMR)
Elanco

Dottie is the lead executional scientist for TCMR at Eli Lilly/Elanco. TCMR facilitates companion animal studies designed to de-risk assets in the Lilly pipeline, as well as assets of potential Lilly partners. At the University of Pennsylvania, Dottie led a sponsored translational research program focusing on the development of outcome assessment instruments for chronic pain in companion animals and applying those instruments to translational studies evaluating the efficacy of novel interventions, such as targeted neurotoxins, in dogs with naturally occurring bone cancer or osteoarthritis.

Dorothy Brown

Senior Research Advisor, Translational Comparative Medical Research (TCMR)
Elanco

Dorothy Brown

Senior Research Advisor, Translational Comparative Medical Research (TCMR)
Elanco

Dottie is the lead executional scientist for TCMR at Eli Lilly/Elanco. TCMR facilitates companion animal studies designed to de-risk assets in the Lilly pipeline, as well as assets of potential Lilly partners. At the University of Pennsylvania, Dottie led a sponsored translational research program focusing on the development of outcome assessment instruments for chronic pain in companion animals and applying those instruments to translational studies evaluating the efficacy of novel interventions, such as targeted neurotoxins, in dogs with naturally occurring bone cancer or osteoarthritis. At Eli Lilly/Elanco, she now directs companion animal studies across institutions in order to leverage high quality, systematic translational data with the goal of improving both human and animal health.

 
Animal Microbiome UK 2019
9-10 Jul 2019
London, UK
The Global Probiotics in Animal Feed Market is poised to grow at a CAGR of around 7.9% over the next decade to reach approximately $6.37 billion by 2025.The European Animal Microbiome Congress brings together leading veterinary researchers, innovative biotechnology companies, feed and strain manufacturers, animal breeders and producers, animal pharmaceutical companies, regulatory bodies, and cutting-edge solution providers to showcase the latest commercially viable research focusing on manipulating the animal microbiome, form successful product development strategies, and facilitate collaborations and business partnering. Techniques and products that manipulate the animal microbiome are set to be the next frontier in superior disease therapeutics, diagnostics, and nutrition in livestock, companion animals, and aquaculture. This conference will showcase unpublished data, new technologies, and translational case studies presented by leading academic and industry experts. 
VIDEO: Recap of Microbiome Invest 2017
 
Microbiome Invest 2018
23 May 2018
Novotel London West, London, UK
The Microbiome Invest Congress 2018 is dedicated to showcasing the most innovative emerging companies and academics with commercially viable research that manipulates the microbiome. Active investors, and multi-national nutrition and pharmaceutical companies will also share their knowledge and perspectives on commercialisation and discuss the most cutting-edge products and research in the microbiome space.
 
Beauty and Money Europe 2019
27 Jun 2019
London, UK
150+ beauty industry executives, from strategic buyers, financial buyers and independent beauty brands, all looking for their next investment, acquisition or business partnering opportunity.